Verseon Nominates VE-4840 as Primary Drug Candidate for Oral Prophylaxis and Treatment of Diabetic Eye Disease

FREMONT, Calif.: FREMONT, Calif., Aug. 5, 2021 /PRNewswire/ -- Verseon today announced that VE-4840 will advance as the company's primary diabetic retinopathy (DR) development candidate after it passed preliminary toxicology studies. Orally administered VE-4840 has also demonstrated significant reduction of diabetes-induced retinal vascular permeability (RVP) in vivo. These results, along...

Click to view original post